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Abstract
Despite the dramatic improvement in the overall survival for patients diagnosed with Wilms’ 
tumor (WT), the outcomes for those that experience relapse have remained disappointing. We 
describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy 
(HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, 
and reported to the Center for International Blood and Marrow Transplantation Research 
(CIBMTR). The 5-year estimates for event free survival (EFS) and overall survival (OS) were 36% 
(95% CI; 29 – 43%) and 45% (95% CI; 38 – 51%) respectively. Relapse of primary disease was 
the cause of death in 81% of the population. EFS, OS, relapse and transplant-related mortality 
(TRM) showed no significant differences when broken down by disease status at transplant, time 
from diagnosis to transplant, year of transplant or conditioning regimen. Our data suggest that 
HDT followed by autologous HCT for relapsed WT is well tolerated and outcomes are similar to 
those reported in the literature. Since attempts to conduct a randomized trial comparing 
maintenance chemotherapy with consolidation versus high-dose chemotherapy followed by stem 
cell transplant have failed, one should balance the potential benefits with the yet unknown long-
term risks. Since disease recurrence continues to be the most common cause of death, future 
research should focus on the development of consolidation therapies for those patients achieving 
complete response to therapy.
INTRODUCTION
Each year approximately 500 children in the United States are diagnosed with Wilms tumor 
(WT).1 The outcomes for children with WT have improved dramatically with the advent of 
multi-modal therapy, and survival rates are currently approaching 90%.2 With improved 
chemotherapy the overall relapse rate for children with WT has decreased to less than 
15%.3–5 However, long term survival for patients who relapse and are re-treated with 
chemotherapy and surgery alone have been disappointing, with approximately 50% of 
patients dying of disease by 4 years.6–9
The identification of prognostic factors associated with risk for treatment failure after 
relapse has allowed for risk-adapted treatment strategies. In the most recent National Wilms’ 
Tumor Study - 5 (NWTS-5) children who relapsed after minimal initial therapy with 
vincristine and actinomycin have a greater than 80% 4-year overall survival (OS) rate.10 
However, the 4-year OS rate was less than 50% for those who relapsed after receiving these 
two drugs plus doxorubicin and radiation.11
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Due to the poor long-term outcomes of patients with relapsed WT, many investigators have 
used high dose therapy (HDT) followed by autologous HCT in a non-randomized fashion 
and reports usually consist of small institutional series or review articles. Since the first 
European Bone Marrow Transplant (EBMT) report, the number of relapsed WT patients 
transplanted in the EBMT registry has continued to grow.12 When compared with historical 
controls of patients treated with conventional chemotherapy, these trials obtained better 
outcomes, with 3- or 4-year OS rates ranging from 60 to 73%.13–17
Taken together, these studies suggest a potential survival advantage of HDT with autologous 
HCT over conventional chemotherapy in patients with relapsed WT and a good response to 
re-induction therapy, although increased toxicity is a major concern. However, this small 
advantage may be a result of the small number of patients enrolled in each study and a 
possible selection bias.
In order to investigate the role of HDT followed by autologous HCT in pediatric patients 
with relapsed WT, we sought to utilize the Center for International Blood and Marrow 
Transplant Research (CIBMTR) database to describe outcomes of patients transplanted from 
1990 to 2013 and reported to CIBMTR.
METHODS
Patients
Data were obtained from the CIBMTR, a working group of more than 500 transplant centers 
worldwide that provide patient, disease, and transplant characteristics including outcomes 
for consecutive transplantations to a statistical center coordinated through the National 
Marrow Donor Program (NMDP). All HCTs have basic information collected; selected 
transplants have more detailed information collected. For this, only information from the 
basic level forms was available. Patients or guardians provided written informed consent for 
data submission and research participation in accordance with the Declaration of Helsinki. 
The Institutional Review Boards of the Medical College of Wisconsin and NMDP approved 
this study.
Eligibility Criteria
Patients with recurrent WT treated with autologous HCT between 1990–2013 who were 
younger than 21 years old at the date of initial diagnosis were eligible for inclusion. Patients 
were excluded if they were untreated prior to transplant, or were treated at a center with low 
follow-up (the percentage of patients who were not dead nor lost to follow-up was less than 
20% at 5-years post-transplant).
Endpoints
The primary objective of this study was to describe event-free survival (EFS) with the 
secondary outcomes being OS, post-HCT relapse, and transplant-related mortality (TRM). 
EFS was defined as survival without relapse or disease progression. Relapse was defined as 
the recurrence of WT. TRM was defined as death in the first 28 days’ post-transplant or 
death in continuous remission. OS was defined as survival from all causes.
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Statistical analysis
The probabilities of EFS and OS were calculated using the Kaplan Meier estimator.18–20 
Ninety-five percent confidence intervals were calculated using log transformation. EFS was 
defined as the time interval between HCT and relapse, disease progression, or death 
whichever occurs first. Patients surviving in remission were censored at the date of last 
follow-up. OS was defined as the time interval between HCT and death from any cause. 
Patients surviving were censored at the date of last follow-up. The cumulative incidences of 
relapse and TRM were estimated using the cumulative incidence function with TRM as the 
competing risk for relapse and relapse as the competing risk for TRM.
In multivariate analysis, the Cox proportional hazards model was used to identify significant 
risk factors. Variables tested in the Cox proportional hazards regression model included 
disease status at transplantation (first pre-transplant relapse versus second or greater pre-
transplant relapse or continuous remission versus persistent/progressive disease versus 
missing), time from diagnosis to transplantation (< 12 months versus 12–18 months versus > 
18 months), graft type (bone marrow [BM] versus peripheral blood stem cells [PBSC]), year 
of transplant (1990–1994 versus 1995–1999 versus 2000–2004 versus 2005–2013) and 
conditioning regimen (alkylating agents [cyclophosphamide+melphalan, busulfan
+cyclophosphamide, busulfan+melphalan, melphalan, cyclophosphamide+thiotepa, 
cyclophosphamide] versus platinum agents [carboplatin+melphalan, cyclophosphamide
+carboplatin, carboplatin]). The assumption of proportional hazards for each factor was 
tested using time-dependent covariates. When the test indicated differential effects over time 
(non-proportional hazards), models were constructed breaking the post-transplant time 
course into two periods, using the maximized partial likelihood method to find the most 
appropriate breakpoint. The proportionality assumptions were further tested. A stepwise 
model selection approach was used to identify all significant risk factors. Factors that were 
significant at a 5% level were kept in the final model. Two-way interactions were tested for 
all variables that remained in the final model. Analysis was performed using SAS version 
9.33 (Cary, NC).
Results
Patient, disease and transplant characteristics of 253 children with WT by transplant period 
and disease status at transplantation are shown in Tables 1 and 2. The median patient age at 
HCT was 6 years (range 1–23), with 135 (53%) patients being female. According to the 
available data, 62% (152/253) of the patients were transplanted while in remission and 25% 
(62/253) of the patients were transplanted with disease present. Among patients transplanted 
in remission, 67% (106/158) of the patients were in CR2 or greater and 20% were in PR at 
time of transplant. The median time from diagnosis to transplant was 18 months (range 5–
208). Fifty-one percent of the patients were transplanted 18 months or longer after their 
diagnosis, 73 (29%) were transplanted 12–18 months after diagnosis and 51 (20%) were 
transplanted less than 12 months after diagnosis.
The most common source of autologous stem cells for patients enrolled on this study was 
PBSC (n=195, 77%). The number of patients transplanted in each study period was: 33 
(13%) between 1990–1994, 67 (26%) between 1995–1999, 52 (21%) between 2000–2004 
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and 101 (40%) between 2005–2013. HCT conditioning included alkylating agents in 142 
(56%) of the patients, 75 patients (30%) received platinum agents and 36 (14%) were 
missing conditioning information. The median follow-up of survivors is 57 months (range 
1–241). Fourteen (6%) patients received a second transplant. Nine (64%) of second HCT 
happened within 2 months of the first transplant and were likely scheduled tandem HCTs, all 
happening after 2000.
The median follow-up of survivors was greater than 92 months (range 1–241) for patients 
treated between 1990 and 2004, and 26 months (range 3–94) for those treated between 2005 
and 2013.
Outcomes
The 5-year EFS and OS rate for all patients were 36% (95% CI; 29 – 43%) and 45% (95% 
CI; 38 – 51%). Figures 1A and 1B show the probabilities of EFS and OS by transplant 
period and Figures 2A and 2B show the probabilities of EFS and OS by disease status at 
transplantation.
Relapse of primary disease was the cause of death in 81% of the patients (104 out of 129 
evaluable deaths). There were no significant differences in 1, 2, 3 and 5-year EFS OS, 
relapse, and TRM estimates when outcomes were analyzed by univariate analysis according 
to disease status at transplant, time from diagnosis to transplant, graft source, conditioning 
regimen and year of transplant (Table 3). Overall the 1 year TRM incidence was low (4–9%) 
and did not vary significantly over the length of the study. An analysis of patients who 
received autologous HCT when not in remission compared with those who were in 
remission did not show significant differences.
Conditioning regimen was the only factor found to be statistically significant by multivariate 
analysis (Table 4). The effect of conditioning regimen on overall mortality changed over 
time. The use of platinum agents was associated with lower mortality in the first 10 months 
after HCT but not thereafter. This time-dependent effect explains why in univariate analysis 
there were no differences in survival by conditioning regimen.
DISCUSSION
Relapsed WT is rare, but outcomes for these patients remain suboptimal. HDT followed by 
autologous HCT has been used to salvage patients with WT who relapse after chemotherapy. 
This retrospective study using the CIBMTR database includes one of the largest numbers of 
patients with recurrent WT treated with high dose chemotherapy followed by autologous 
HCT reported to date.
The number of HCT per year has not changed significantly since 1995. However, over time, 
there was a clear trend in change of practice from BM as a stem cell source to PBSC. During 
the first analysis period, 1990–94, BM was the most common source of stem cells (70%) 
and it was almost completely replaced by PBSC (93%) in the most recent period, 2005 to 
2013.
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The conditioning regimens were varied and included alkylating agents for 142 (56%) 
patients. Platinum-containing regimens became more common during the most recent period 
(2005–2013). The large number of different conditioning regimens used in the treatment of 
these patients, highlights one of the biggest challenges for the development of a common 
approach for these patients. Although our data identified that the use of platinum agents was 
associated with lower mortality in the first 10 months’ post-transplant, this effect was no 
longer seen after that.
In a recent manuscript, Ha et al, reviewed the data from 19 relevant publications in an 
attempt to determine the role of HDT followed by HCT in the treatment of relapsed WT. The 
authors used pooled data of 1226 patients to compare the overall 3-year EFS and OS 
between patients treated with HDT followed by HCT with dose treated without HDT 
(conventional chemotherapy).21 The median 3-year EFS and OS for patients who did not 
received HDT was 47.6% (1.76–79.83%) and 47.5% (3.7–100%), respectively, compared to 
47% (3.7–100%) and 47.5% (12.5–100%) for those treated with HDT followed by HCT.21 
The authors concluded that the evidence suggest the value of HDT followed by HCT, 
particularly for those in the highest risk relapse group based on initial stage, histology, initial 
treatment received and prior relapse.
A recent international meta-analysis conducted by Presson et al, to provide additional 
insights in the role of HDT followed by HCT revealed that the patients most likely to benefit 
from this approach were those initially treated with four or more chemotherapeutic agents 
and those with multiple relapses or progression on salvage therapy. 22
The biggest limitation of our study is the fact that this study is a retrospective registry-based 
analysis and that the available data originates from basic level forms, and therefore, did not 
include the following diagnosis variables: histology, site of metastases, stage of disease, 
genetic syndrome, tumor spillage, and radiation. The following pre-transplant variables were 
also not available for the majority of the patients: site, time from diagnosis to relapse. 
Differently than the 2 studies mentioned above, this lack of detailed data did not allow us to 
investigate if there is a risk-group of patients that could benefit from the use HDT followed 
by autologous HCT. Consequently our observation of an absence in EFS and OS by disease 
status must be interpreted with caution as several pertinent disease and treatment 
characteristics including histopathological features at diagnosis were not studied.
Unlike than other previous reports,3,5,7,10–16 our results were not influenced by time from 
diagnosis to transplant, graft source or conditioning regimen. The survival outcomes found 
in this study are no different than those obtained in previous reports using systemic 
chemotherapy alone or HDT followed by HCT21–22. Overall, the use of HDT followed by 
autologous HCT appears to be useful for the full spectrum of disease states. However, the 
retrospective nature, heterogeneous nature of relapsed Wilms tumor relatively small patient 
numbers limit this study. The lack of a complete supplemental data set limits the strength of 
the conclusions and is a reminder of the importance of data collection and submission, 
particularly in rare diseases.
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Our data, including considering its limitations together with those from previous studies 
suggest that HDT followed by autologous HCT for relapsed WT is well tolerated. The EFS 
and OS for our study was not different than those reported by Ha et al21 and Presson et al22 
for patients with relapsed WT treated with HCT or standard chemotherapy. Since attempts to 
conduct a randomized trial comparing maintenance chemotherapy with consolidation with 
high-dose chemotherapy followed by stem cell transplant have failed, one should balance the 
potential benefits of such approach with the yet unknown long term risks associated with 
this approach when deciding which patient should be submitted HDT followed by 
autologous HCT. Since disease recurrence continues to be the most common cause of death 
for patients who received standard chemotherapy or HDT followed by autologous HCT, 
future research should focus on the development of consolidation therapies for those patients 
achieving complete response to therapy.
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Figure 1. 
Figure 1A: Event Free Survival after HCT by Year of transplant
Figure 1B: Overall Survival after HCT by Year of transplant
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Figure 2. 
Figure 2A: Event Free Survival after HCT by Disease status at transplantation
Figure 2B: Overall Survival after HCT by Disease status at transplantation
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Table 2
Characteristics of patients who underwent autologous transplant for Wilms Tumor from 1990–2013, as 
registered to the CIBMTR, by Disease status at transplantation.
Variable In remission Disease present Missing
Number of patients 158 62 33
Region of center
 US 129 (82) 49 (79) 23 (70)
 Canada 11 (7) 6 (10) 1 (3)
 International 18 (11) 7 (11) 9 (27)
Age at diagnosis, years, median (range) 5 (<1–21) 4 (<1–20) 4 (<1–19)
Age at diagnosis
 0–4 90 (57) 39 (63) 18 (55)
 5–9 55 (35) 17 (27) 12 (36)
 10+ 13 (8) 6 (10) 3 (9)
Age at transplant, years, median (range) 7 (2–23) 6 (2–21) 7 (1–21)
Age at transplant
 0–4 37 (23) 24 (39) 8 (24)
 5–9 91 (58) 25 (40) 20 (61)
 10+ 30 (19) 13 (21) 5 (15)
Gender
 Male 66 (42) 34 (55) 16 (48)
 Female 92 (58) 27 (44) 16 (48)
 Missing 0 1 (2) 1 (3)
Disease status
 CR2 85 (54) 0 0
 CR3+ 21 (13) 0 0
 CR unknown * 20 (13) 0 0
 REL1 0 28 (45) 0
 REL2 0 5 (8) 0
 REL3 0 3 (5) 0
 REL unknown 0 8 (13) 0
 Progression 0 9 (15) 0
 Stable disease 0 9 (15) 0
 Partial response * 32 (20) 0 0
 Missing 0 0 33
Time from diagnosis to transplant, months (continuous) 18 (5–129) 17 (5–208) 17 (6–113)
Time from diagnosis to transplant, months (categorical)
 < 12 22 (14) 17 (27) 12 (36)
 12–18 51 (32) 17 (27) 5 (15)
 ≥ 18 85 (54) 28 (45) 16 (48)
Graft type
 BM 23 (15) 21 (34) 10 (30)
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Variable In remission Disease present Missing
 PBSC 133 (84) 40 (65) 22 (67)
 Missing 2 (1) 1 (2) 1 (3)
Regimen groups **
 Alkylating agents 89 (56) 39 (63) 14 (42)
 Platinum agents 55 (35) 15 (24) 5 (15)
 Missing 14 (9) 8 (13) 14 (42)
Years of transplant
 1990–1994 10 (6) 15 (24) 8 (24)
 1995–1999 34 (22) 20 (32) 13 (39)
 2000–2004 32 (20) 13 (21) 7 (21)
 2005–2013 82 (52) 14 (23) 5 (15)
Follow-up of survivors, months, median (range) 49 (1–241) 73 (1–239) 33 (1–152)
Abbreviations: CR = Complete remission, REL = Relapse, BM = Bone marrow, PBSC = Peripheral Blood Stem Cells, CY = Cyclophosphamide, 
LPAM = Melphalan, BU = Busulfan, THIO = Thiotepa, CARB = Carboplatinum.
*
Determined patients not in CR1 or PR1 based on duration of time from diagnosis to transplant.
**Alkylating agents are defined as CY+LPAM, BU+CY, BU+LPAM, LPAM, CY+THIO, CY;
Platinum agents are defined as CARB+LPAM, CY+CARB, CARB.
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